Affibody 
Welcome,         Profile    Billing    Logout  
 1 Product   175 Diseases   1 Product   3 Trials   77 News 


12345678910111213...6061»
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Journal:  Rilonacept use in lupus pericarditis. (Pubmed Central) -  Mar 25, 2024   
    Rilonacept successfully treated lupus pericarditis in this case series. Rilonacept should be considered for the treatment of lupus pericarditis.
  • ||||||||||  izokibep (ABY-035) / ACELYRIN
    Enrollment closed:  Hidradenitis Suppurativa Study of Izokibep (clinicaltrials.gov) -  Mar 22, 2024   
    P3,  N=189, Active, not recruiting, 
    Results confirm that HBP may be an early biomarker of poor outcome among pre-selected patients at risk from COVID-19 pneumonia.ClinicalTrials.gov registration NCT04357366. Recruiting --> Active, not recruiting
  • ||||||||||  Kineret (anakinra) / SOBI
    Enrollment open:  Anakinra in Dengue With Hyperinflammation ( AnaDen ) (clinicaltrials.gov) -  Mar 21, 2024   
    P2,  N=160, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Remicade (infliximab) / J&J, Kineret (anakinra) / SOBI
    Review, Journal:  Treatment of multisystem inflammatory syndrome in children. (Pubmed Central) -  Mar 21, 2024   
    However, there remains a critical need for greater standardization in treatment protocols, alongside the pressing necessity for more robust and meticulously conducted studies to deepen our understanding of these protocols. Supplementary file1 (MP4 208044 kb).
  • ||||||||||  Kineret (anakinra) / SOBI
    Retrospective data, Journal:  Effectiveness and safety of IL1 inhibition with anakinra in chronic refractory idiopathic myocarditis. (Pubmed Central) -  Mar 21, 2024   
    As such, it is included in the EUA to identify patients that fall within the authorized population for whom the known and potential benefits outweigh the known and potential risks of anakinra. All patients had a rapid improvement in systemic inflammation, cardiac function, and arrhythmic burden with anti-IL1 therapy, indicating that anakinra may be an effective treatment in chronic active idiopathic myocarditis, refractory to standard treatment.
  • ||||||||||  Kineret (anakinra) / SOBI
    Retrospective data, Journal:  Efficacy of colchicine in addition to anakinra in patients with recurrent pericarditis. (Pubmed Central) -  Mar 20, 2024   
    All patients had a rapid improvement in systemic inflammation, cardiac function, and arrhythmic burden with anti-IL1 therapy, indicating that anakinra may be an effective treatment in chronic active idiopathic myocarditis, refractory to standard treatment. The addition of colchicine on top of anakinra treatment could be helpful to reduce recurrences and prolong the recurrence-free survival.
  • ||||||||||  Kineret (anakinra) / SOBI
    Journal:  Subcutaneous anakinra in the management of refractory MIS-C in France. (Pubmed Central) -  Mar 11, 2024   
    Subcutaneous anakinra appears to be a safe and effective treatment for the management of heart failure or MAS in MIS-C patients. The value of IVIG in these two situations remains to be reviewed.
  • ||||||||||  Kineret (anakinra) / SOBI
    Journal:  P2X7 receptor inhibition alleviates mania-like behavior independently of interleukin-1?. (Pubmed Central) -  Mar 6, 2024   
    We tested in a mouse model of the subchronic amphetamine (AMPH)-induced hyperactivity whether P2X7R inhibition alleviated mania-like behavior through IL-1?...The NLRP3 inhibitor MCC950 failed to reduce AMPH-induced locomotion in WT mice, whereas the IL-1 receptor antagonist anakinra slightly increased it...In wild-type and IL-1?/?-knockout female mice, JNJ-47965567 was also effective in attenuating AMPH-induced hyperlocomotion. This study suggests that AMPH-induced hyperactivity is modulated by P2X7Rs, but not through IL-1?.
  • ||||||||||  Kineret (anakinra) / SOBI
    Aberrant activation and perpetuation of lung wound response facilitates osteosarcoma metastasis (Section 11) -  Mar 5, 2024 - Abstract #AACR2024AACR_8684;    
    Metastatic colonization requires transformation of the local lung microenvironment into a fibrotic, non-resolving, cytokine-rich, wound-like state that is both provoked and sustained by tumor-epithelial interactions. These insights have identified several potential therapeutic approaches to prevent metastatic colonization and treat established metastases.
  • ||||||||||  Kineret (anakinra) / SOBI
    Interleukin-1 upregulates dual oxidase 2 expression and ROS production in human pancreatic cancer cells (Section 4) -  Mar 5, 2024 - Abstract #AACR2024AACR_8299;    
    Administration of the anti-inflammatory antibody anakinra (an IL-1R1 antagonist) either in conjunction with or after prolonged treatment with IL-1 in vitro ablated induction of DUOX2/DUOXA2 and of IL-8 (CXCL8), a chemokine essential for neutrophil recruitment and a potent promoter of angiogenesis...Because IL-1 signaling is known to affect various acetylation/methylation events in epithelial cells, we evaluated the effect of administering the histone acetyltransferase (HAT) inhibitor A-485 with IL-1; we found that A-485 significantly diminished cytokine-induced DUOX2/DUOXA2 upregulation; however, CXCL8 induction was unchanged. These studies suggest that epigenetic modulation of PDAC cells by IL-1 could contribute to DUOX2-induced ROS production and ROS-related inflammatory stress in the PDAC microenvironment.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI, Ilaris (canakinumab) / Novartis
    Review, Journal:  Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options. (Pubmed Central) -  Mar 5, 2024   
    Other treatment options are being considered since several molecules involved in the disease pathophysiology can be targeted through various mechanisms. This review will provide a broad overview of AOSD pathophysiology, insights into specific organ manifestations and the currently available treatments with the identification of potential therapeutic targets involved in AOSD pathogenesis will be outlined.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI, Ilaris (canakinumab) / Novartis
    Journal:  Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy. (Pubmed Central) -  Mar 5, 2024   
    This review will provide a broad overview of AOSD pathophysiology, insights into specific organ manifestations and the currently available treatments with the identification of potential therapeutic targets involved in AOSD pathogenesis will be outlined. Anti-IL-1/-6 therapies can mask the clinical and laboratory features of MAS, and proposed guidelines for MAS classification criteria may not be met.
  • ||||||||||  Kineret (anakinra) / SOBI
    Trial completion date:  Treatment of Macrophage Activation Syndrome (MAS) With Anakinra (clinicaltrials.gov) -  Mar 2, 2024   
    P1,  N=40, Active, not recruiting, 
    We propose a risk-based strategy to encourage heightened clinician awareness of cold sepsis, with a view to reducing NRM. Trial completion date: Dec 2023 --> Apr 2024
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
    Review, Journal:  Second-line immunotherapy in new onset refractory status epilepticus. (Pubmed Central) -  Mar 2, 2024   
    There continues to be interest in the utilization of early cytokine measurements to guide treatment selection and response. Prospective studies are necessary to understand the role of early immunomodulation and its associations with epilepsy and functional outcomes.
  • ||||||||||  Kineret (anakinra) / SOBI
    Clinical, Journal, Adverse events:  Adverse events of biological agents in pediatric rheumatologic diseases. (Pubmed Central) -  Feb 28, 2024   
    Drug rash with eosinophilia and systemic symptoms (DRESS) occurred in 2 patients on anakinra, and anaphylaxis occurred in 1 patient on anti-IL6...The physician should be vigilant for latent TB in patients exposed to BA for more than 2?years. While local skin reactions are more prevalent in patients receiving anti-IL1, severe skin reactions such as DRESS may also occur.
  • ||||||||||  Review, Journal:  Therapeutic Potential of IL-1 Antagonism in Hidradenitis Suppurativa. (Pubmed Central) -  Feb 28, 2024   
    The aim of this narrative review is to describe the pathological dysregulation of IL-1 family members in HS and to provide an update on therapeutic strategies targeting IL-1 family cytokine signaling. Further clinical and preclinical data may likely lead to the enrichment of the therapeutic armamentarium of HS with IL-1 family cytokine antagonists.
  • ||||||||||  Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa, Ilaris (canakinumab) / Novartis
    Journal:  Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA). (Pubmed Central) -  Feb 26, 2024   
    Recently published provisional points to consider from the European Alliance of Associations for Rheumatology (EULAR) and American College of Rheumatology (ACR) provide diagnosis, management, and monitoring recommendations for four IL-1-mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), and deficiency of the IL-1 receptor antagonist (DIRA). The goal of this paper is to aid health care professionals by providing a practical approach to diagnosis and management of these four IL-1 mediated SAIDs on the basis of the recent EULAR/ACR recommendations.
  • ||||||||||  Kineret (anakinra) / SOBI
    Journal:  A pivotal role for the IL-1? and the inflammasome in preterm labor. (Pubmed Central) -  Feb 25, 2024   
    was essential in macrophage/myocyte crosstalk during labor. These findings provide novel innovative approaches in the management of preterm labor, specifically the use of an inflammasome inhibitor to block the precursor stages of labor before the acquisition of the contractile phenotype.
  • ||||||||||  Arcalyst (rilonacept) / Regeneron, Kiniksa
    Rilonacept use in lupus pericarditis () -  Feb 25, 2024 - Abstract #LUPUS2024LUPUS_335;    
    Conclusion Rilonacept successfully treated lupus pericarditis in this case series. Rilonacept should be considered for the treatment of lupus pericarditis.
  • ||||||||||  Stelara (ustekinumab) / J&J, Kineret (anakinra) / SOBI, Entyvio (vedolizumab) / Takeda
    Review, Journal:  Inflammatory Complications in Chronic Granulomatous Disease. (Pubmed Central) -  Feb 24, 2024   
    Immunosuppressive agents have traditionally been used to treat these complications, but their use is hindered by the fact that CGD patients are predisposed to infection. Novel therapeutic agents, like anti-TNFa monoclonal antibodies, anakinra, ustekinumab, and vedolizumab offer promise for the future, while hematopoietic stem cell transplantation should also be considered in these patients.
  • ||||||||||  Kineret (anakinra) / SOBI
    Review, Journal:  Analysis of Anakinra Therapy for the Deficiency of Interleukin-1 Receptor Antagonist through Clinical Evidence. (Pubmed Central) -  Feb 24, 2024   
    Novel therapeutic agents, like anti-TNFa monoclonal antibodies, anakinra, ustekinumab, and vedolizumab offer promise for the future, while hematopoietic stem cell transplantation should also be considered in these patients. Considering the inconsistency and certain variations from clinical research influenced by specific conditions, this review along with the data analysis confirms the efficacy and safety of anakinra treatment for DIRA.
  • ||||||||||  Review, Journal:  Biomaterials Functionalized with Inflammasome Inhibitors-Premises and Perspectives. (Pubmed Central) -  Feb 23, 2024   
    Moreover, phytochemicals inhibit the inflammasomes by neutralizing reactive oxygen species. Biomaterials functionalized by the adsorption of therapeutic agents onto different nanomaterials could represent future research directions to facilitate multimodal and sequential treatment in oral pathologies.
  • ||||||||||  Kineret (anakinra) / SOBI
    The Cutaneous Manifestations of VEXAS Syndrome () -  Feb 20, 2024 - Abstract #AAD2024AAD_3381;    
    Severe injection site reactions in patients treated with anakinra were a frequent finding (12/16, 75%), including ulceration (2/12, 17%) and abscess formation (1/12, 8%)...Detecting any of these signs in older male patients with constitutional symptoms warrants genetic assessment for VEXAS. Early diagnosis facilitates timely management, potentially enhancing overall clinical outcomes for VEXAS patients.
  • ||||||||||  Kineret (anakinra) / SOBI, Arcalyst (rilonacept) / Regeneron, Kiniksa, Ilaris (canakinumab) / Novartis
    IL-1 () -  Feb 20, 2024 - Abstract #AAD2024AAD_2215;    
    Objectives We performed a systematic review of prospective and retrospective studies, as well as case reports and series, to determine whether IL-1? inhibitors (canakinumab, anakinra and rilonacept) improve patients
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Kineret (anakinra) / SOBI, Cytogam (cytomegalovirus immune globulin intravenous(human)) / Kamada
    The Unfortunate Trifecta: Tuberculosis, EBV, and CMV Induced Hemophagocytic Lymphohistiocytosis (Marriott Marquis San Diego Marina, Pacific Ballroom 15-17 (Ground Floor, North Tower)) -  Feb 20, 2024 - Abstract #ATS2024ATS_8170;    
    Case report: A 52-year-old male with history of end-stage renal disease underwent deceased donor kidney transplant two years prior to presentation and was maintained on mycophenolate, tacrolimus, and prednisone...Broad infectious workup resulted in CMV and EBV viremia, treated with intravenous valganciclovir and cytogam...High clinical suspicion for HLH (H-score 218, 93-96% probability) prompted therapy with dexamethasone and anakinra (IL-1 blocker) following biopsy...Globally, cases of MTB induced HLH have a 54% survival rate, with diagnostic delay resulting in delay of appropriate antimicrobials and worse outcomes. These diagnostic delays warrant consideration of empiric MTB therapy for immunocompromised patients under suspicion for HLH.
  • ||||||||||  Kineret (anakinra) / SOBI, Ilaris (canakinumab) / Novartis
    VV-ECMO as a Bridge to Recovery in ARDS Secondary to Adult-Onset Still's Disease (TDP06) -  Feb 20, 2024 - Abstract #ATS2024ATS_5898;    
    AOSD is a rare systemic autoinflammatory disorder with a poorly understood multifactorial pathophysiology hypothesized to be perpetuated by dysregulated activation of the innate immune system...Multisystem organ failure may be a deterrent from VV-ECMO use given its outcome prediction in other disease states. However, we hope this case provides insight into its potential as a bridge to recovery in this population which otherwise has a poor prognosis.
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Kineret (anakinra) / SOBI
    When Fevers and Hypoxia Collide: A Case of Adult-Onset Still's Disease (TDP11) -  Feb 20, 2024 - Abstract #ATS2024ATS_5658;    
    He was empirically started on valganciclovir but continued to have persistent symptoms...The patient was started on anakinra and corticosteroids and had clinical improvement with resolution of his oxygen requirement in under 48 hours...This case not only represents a rare presentation of AOSD, it also highlights the importance of including AOSD as part of the differential diagnosis for patients with persistent symptoms and other signs of systemic involvement despite a trial of antibiotics. Additionally, as patients with AOSD are at increased risk of flares, it is imperative that physicians recognize these vulnerable patients to reduce morbidity and mortality associated with this disease.